The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
Pharmaceutics, 2022 Poly (adenosine diphosphate [ADP]–ribose) polymerases inhibitors (PARPi), the first clinically approved drug that exhibits synthetic lethality, are moving to the forefront of cancer treatments.
Lisha Cai, Xiaoling Xu, Wei Chen
doaj +1 more source
Research Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway [PDF]
, 2010 Introduction: Mechanical ventilation (MV) can injure the lungs and contribute to an overwhelming inflammatory response, leading to acute renal failure (ARF).
Vaschetto, R. +7 more
core +2 more sources
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
Biomedicines, 2021 Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential ...
Maritza P. Garrido +5 more
doaj +1 more source
Biochemical Effects of Exercise on a Fasciocutaneous Flap in a Rat Model. [PDF]
, 2017 Importance: An overwhelming amount of data suggest that cardiovascular exercise has a positive effect on the mind and body, although the precise mechanism is not always clear.
Aksamitiene, Edita +8 more
core +3 more sources
Indian Journal of Medical and Paediatric Oncology, 2020 Poly(adenosine diphosphate ribose) polymerase inhibitors (PARPis), when used in patients harboring tumor with homologous recombination deficiency, with or without BRCA mutation, have shown favorable outcomes in relapsed, advanced metastatic breast and ...
Avinash Pandey, Joydeep Ghosh
doaj +1 more source
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling [PDF]
, 2015 Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment.
Chang, Paul
core +1 more source
Failure to detect "cap" structures in mitochondrial DNA-coded poly(A)-containing RNA from HeLa cells [PDF]
, 1978 The structure of the 5'-termini has been investigated in mitochondrial DNA- coded poly(A)-containing RNA from HeLa cells. For this purpose, mitochondrial RNA isolated from cells labeled for 3 hours with [32P]orthophosphate in the presence of 20 µg/ml ...
Amalric, François +3 more
core +1 more source
Frontiers in Cell and Developmental Biology, 2022 Homologous recombination DNA repair (HR) is a complex DNA damage repair pathway and an attractive target of inhibition in anti-cancer therapy. To help guide the development of efficient HR inhibitors, it is critical to identify compensatory HR sub ...
Platon Selemenakis +7 more
doaj +1 more source
Specific inhibition of the differentiation of Trypanosoma cruzi [PDF]
, 2004 The morphological transformation of Trypanosoma cruzi amastigotes was studied in both mammalian cells and an extracellular differentiation system. Inhibitors of ADP-ribosyl transferase were found to block differentiation in both cases, without affecting ...
Williams, GT
core +1 more source
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
Frontiers in Oncology, 2020 The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy.
Elisena Franzese +6 more
doaj +1 more source